Integrated Biomarker and Imaging Study
Initiatives
-
IBIS-2 was a multi-center, randomized, double blind, placebo-controlled, parallel group study designed to examine the effects of once daily Darapladib Enteric Coated Tablet 160 mg on intermediate cardiovascular endpoints compared to placebo
- Start Year
- 2008
- Funding
- GlaxoSmithKline
Visit IBIS-2
| Investigators | Contacts |
|---|---|
|
Design
- Study design
- Clinical trial cohort
- Follow Up
- The study evaluated safety and tolerability over the 1-year treatment duration
Marker Paper
Serruys PW, Garcia-Garcia HM, Buszman P, et al. for the IBIS-2 Investigators. Direct effects of the lipoprotein-associated phospholipase A2 inhibitor, darapladib, on human coronary atherosclerotic plaque. Circulation. 2008;118:1172-82.
Recruitment
- Sources of Recruitment
-
- Individuals
Number of participants
- Number of participants
- 323
- Number of participants with biosamples
- Supplementary Information
- Subjects aged 33-82 years from 10 countries in Europe (Denmark, Netherlands, Germany, Switzerland, Poland, Austria, Spain, Norway, Belgium, Czech Republic). placebo (n = 151)
Access
Availability of data and biosamples
| Data | |
| Biosamples | |
| Other |